Our News
Research report: MST Access updates BCAL coverage
14 December, 2022
In an updated research report on BCAL Diagnostics, MST Access derived a medium-term valuation of $0.21 per share. See link for the full report: https://mcusercontent.com/f47fb65e7d95c457ef73365a3/files/99a26bda-5c43-18c2-e7f8-d7eebc91163b/MST_Access_BDX_Update_14Dec22.pdf
Event: Early detection technologies in breast cancer
12 October, 2022
As part of breast cancer awareness month in October, BCAL is joining with Volpara Health to host an event discussing the latest innovations in early breast cancer detection. More details/register.
Event: Breast Cancer Awareness Month Doctor's Night at Sydney Breast Clinic
19 October, 2022
As part of breast cancer awareness month in October, Sydney Breast Clinic is hosting a discussion for Doctors on the latest innovations in early breast cancer detection. More details/register.
BCAL Enters US Product Development Agreement with Precion
28 June, 2022
We are pleased to announce BCAL has entered an agreement with US company Precion Inc. for the next stage of development of the Company’s blood based test to detect breast cancer. The move marks an important milestone as BCAL aggressively works to commercialise this valuable product and make it available to women. Read more here.
Recent Analysis Significantly Improves Commercial Prospects
8 February, 2022
We are delighted to report recent results of analysis of its scientific data carried out independently by its Australian team and by a highly regarded team of international diagnostic experts. Read more here, with deeper detail here.
Letter to Shareholders
16 November, 2021
Executive Chair Jayne Shaw has provided a comprehensive business update for shareholders, which can be viewed in full here
BCAL Diagnostics Breast Cancer Awareness Month – Education Session
October, 2021
On Wednesday we heard from BCAL’s CEO Jayne Shaw and a panel of specialists in the Breast Cancer industry. Thank you for those who attended we were overwhelmed with the level of interest.
We announced last week that BCAL Diagnostics has opened a clinical research trial based in Sydney. A research project to fond way of using blood test to detect Breast Cancer. For more information click here
For those that missed the event, you can watch the session here.
BCAL Diagnostics Lists on the ASX
July 2021
The BCAL Diagnostics IPO featured The Australian Financial Review
'A host of well known funds, dealmakers and business figures have bought into the float of soon-to-be-listed small cap healthcare company BCAL, ahead of its listing early next week.'
The team thanks its new and existing shareholders for their support.
Partnership Update
2020
BCAL Diagnostics Joins Sydney Knowledge Hub And Sydney Mass Spectrometry - The University Of Sydney
Heads Over Heels
2019
Jayne Shaw Represents BCAL Diagnostics at Heads Over Heels in Melbourne
BCAL Wins "Win The Future" Contest For International Entrepreneurs in Oceania Programme
2019
Jayne Shaw and Peter Beaumont (Litmus) Represent BCAL Diagnostics And Win "Win The Future" Contest For International Entrepreneurs in Oceania Programme
Ron Philips and Amani Batarseh Share BCAL Diagnostics Progress
2019
This is your News Article. It’s a great place to update your visitors about industry news, or publish relevant announcements about your company. Been in the press recently? Don’t keep it to yourself! Let visitors know about it, and add a link to the original article or write-up.
2016
BCAL Dx presented at the final global round of the 1776 Challenge Cup. This follows BCAL Dx’s successful regional round in Singapore earlier this year.
BCAL Dx was one of 60 finalists in the global round and one of only five companies to progress through to the global round from the Asia-Pacific regional finals.
The Challenge has taken place over the last six months, in 45 cities around the world. Judges had to select from over 1000 startups to progress through to the regional finals, culminating in the global finals with only a handful organisations – of which BCAL Dx was one.
The Challenge was an effective networking opportunity for BCAL Dx, with the opportunity to meet a number of connectors and potential investment partners with a specific interest in medical biotechnology. BCAL Dx was also hosted by the staff of the Australian Embassy, where we discussed the expanding biotech market and how to leverage Australia-US relations in this space.
1776 is a global incubator and seed fund helping startups transform industries that impact millions of lives every day—education, energy & sustainability, health, transportation and cities.
2016
BCAL Dx successfully secured patents in Australia and Japan. BCAL Dx has an exclusive global license to the blood testing technology from the University of Louisville (UoL) in the US. We have been working with the UoL over the last three years to prosecute the patents. In May 2016, the Japanese patent was granted and in September 2016 the Australian patent was granted. We look forward to updating you soon on the granting of the US and Europe patents.
2015
BCAL Dx signs a $700,000 research contract with University of Kentucky to undertake blind trials on invasive ductal cancer and to determine the accuracy of the test on other breast cancers.